ANEB
Anebulo Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.26
+0.00%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.26
From 52W high−89.76%
Volume100.00
Market cap$10.68M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$0.26
From 52W high
−89.76%
Volume
100.00
Market cap
$10.68M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
48.2
MomentumView details →
1D Return
+0.00%
YTD Return
−74.26%
SummaryUpdated Dec 1, 2025
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) is a clinical-stage biotechnology company founded in 2020 and based in Lakeway, Texas. The company went public in May 2021 and focuses on developing treatments for acute cannabinoid intoxication and substance addiction disorders. As a pre-revenue biotech company, Anebulo is currently advancing its lead drug candidate through clinical trials while seeking to address the growing public health concerns related to cannabis overdoses and addiction.
Similar companies
Latest newsMore news →
No recent news for ANEB.